ReviewThe American journal of surgical pathology2016
The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship.
Review in The American journal of surgical pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 273 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
273 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Key Characteristics of Database Studies on Drug Effectiveness in the Postmarketing Stage: A Systematic Review.Pharmaceutical medicine · 2021Pooled it
- Iodine Staining With Distance Countdown Improving the Safety for Reduction of Adverse Events: A Randomized Controlled Trial.Clinical and translational gastroenterology · 2025Trial
- Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis.Journal of Crohn's & colitis · 2024Trial
- Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population-based analysis.Cancer medicine · 2022Trial
- Development and validation of an interpretable Random Forest model for predicting recurrence after endoscopic submucosal dissection in superficial oesophageal squamous cell carcinoma.Annals of medicine · 2026Article
- Age-dependent relative and absolute benefit of radiotherapy after breast-conserving surgery: a population-based analysis using SEER data.Breast cancer research and treatment · 2026Article
- Clinicopathological, multimodal treatment, and survival patterns for men with breast cancer in England and Wales: a population-based cohort study.EClinicalMedicine · 2026Article
- A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions.Nature reviews. Clinical oncology · 2026Review
- Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex.American journal of hematology · 2026Observational
- Development and internal validation of a prognostic model for esophageal cancer liver metastases using the Surveillance, Epidemiology, and End Results database.Journal of thoracic disease · 2026Article
- Cause-specific mortality in a population-level cohort of pancreatic cancer patients following chemotherapy: A SEER-based study.Medicine · 2026Article
- Explainable machine-learning prediction of overall and cancer-specific survival in adult triple-negative breast cancer using SEER: a comparative study of nomograms and random survival forests.Translational cancer research · 2026Article
- Development and validation of a nomogram for overall survival in pancreatic solid pseudopapillary neoplasm: a population-based study.Scientific reports · 2026Article
- Article
- Surgical outcomes and quality of life in octogenarians with early-stage non-small cell lung cancer: a prospective cohort study.Lancet regional health. Americas · 2026Article
- Clinicopathologic Determinants of Overall Survival in Adrenocortical Carcinoma: A SEER-Based Population Study.Cancers · 2026Article
- Association of surgical resection with survival in retroperitoneal leiomyosarcoma based on SEER propensity score matching and machine-learning models.Scientific reports · 2026Article
- Prognostic determinants and survival outcomes in epithelioid sarcoma: A contemporary population-based analysis of 1123 patients.Medicine · 2026Article
- Personalized survival predictions in chromophobe renal cell carcinoma: development of a machine learning-based web tool.International urology and nephrology · 2026Article
- Factors Associated With Rare Pediatric Cancer Trial Enrollment: A Report From the Children's Oncology Group Rare Tumors Committee.Pediatric blood & cancer · 2026Article
213 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute collects data on cancer diagnoses, treatment, and survival for approximately 30% of the United States (US) population. To reflect advances in research and oncology practice, approaches to cancer control are evolving from simply enumerating the development of cancers by organ site in populations to including monitoring of cancer occurrence by histopathologic and molecular subtype, as defined by driver mutations and other alterations. SEER is an important population-based resource for understanding the implications of pathology diagnoses across demographic groups, geographic regions, and time and provides unique insights into the practice of oncology in the US that are not attainable from other sources. It provides incidence, survival, and mortality data for histopathologic cancer subtypes, and data by molecular subtyping are expanding. The program is developing systems to capture additional biomarker data, results from special populations, and expand biospecimen banking to enable cutting-edge cancer research and oncology practice. Pathology has always been central and critical to the effectiveness of SEER, and strengthening this relationship in this modern era of cancer diagnosis could be mutually beneficial. Achieving this goal requires close interactions between pathologists and the SEER program. This review provides a brief overview of SEER, focuses on facets relevant to pathology practice and research, and highlights the opportunities and challenges for pathologists to benefit from and enhance the value of SEER data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.